Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Revenue of Leap Therapeutics, Inc. (LPTX)
Revenue in 2023 (TTM): $
According to Leap Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Leap Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-427,000 | $-80,987,000 | $-81,414,000 | $-81,414,000 |
| 2022 | $ | $-415,000 | $-53,980,000 | $-54,449,000 | $-54,596,000 |
| 2021 | $1.5 M | $1.5 M | $-40,014,000 | $-40,611,000 | $-40,587,000 |
| 2020 | $1.5 M | $1.5 M | $-26,809,000 | $-27,516,000 | $-27,514,000 |
| 2019 | $ | $-776,000 | $-32,104,000 | $-32,903,000 | $-32,900,000 |
| 2018 | $ | $-49,000 | $-23,050,000 | $-23,118,000 | $-23,138,000 |
| 2017 | $ | $-48,000 | $-29,714,999 | $-29,884,000 | $-29,727,000 |
| 2016 | $ | $-25,000 | $-24,374,000 | $-25,632,000 | $-25,632,000 |
| 2015 | $ | $ | $-11,921,000 | $-20,951,000 | $-21,103,000 |
| 2014 | $ | $ | $-19,729,000 | $-25,420,000 | $-25,451,000 |
| 2013 | $ | $ | $-13,230,000 | $-18,175,000 | $-18,324,000 |
| 2012 | $ | $ | $-6,983,000 | $-7,756,000 | $-7,756,000 |